The role of inhaled insulin in the treatment of type 2 diabetes

Journal of Diabetes and its Complications

Volumn 22, Issue 6, 2008, Pages 420-429

  Davis, Stephen N ^a  

^a VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Barriers; Inhaled insulin; Injection; Type 2 diabetes

Indexed keywords

ALPHA GLUCOSIDASE INHIBITOR; BIGUANIDE DERIVATIVE; DIPEPTIDYL PEPTIDASE IV INHIBITOR; EXENDIN 4; GLITAZONE DERIVATIVE; HUMAN INSULIN; INSULIN; INSULIN ANTIBODY; INSULIN GLARGINE; INSULIN LISPRO; INSULIN SENSITIZING AGENT; INSULIN ZINC SUSPENSION; ISOPHANE INSULIN; MEGLITINIDE; METFORMIN; ORAL ANTIDIABETIC AGENT; PRAMLINTIDE; RECOMBINANT HUMAN INSULIN; ROSIGLITAZONE; SULFONYLUREA; SULFONYLUREA DERIVATIVE;

ARTICLE; BEDTIME DOSAGE; COST; COUGHING; DRUG DELIVERY SYSTEM; DRUG WITHDRAWAL; EXERCISE; GLYCEMIC CONTROL; HUMAN; HYPOGLYCEMIA; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN TREATMENT; LIFESTYLE MODIFICATION; LUNG FUNCTION; MORBIDITY; MORTALITY; NON INSULIN DEPENDENT DIABETES MELLITUS; PATIENT SATISFACTION; PRIORITY JOURNAL; SIDE EFFECT; WEIGHT GAIN; WEIGHT REDUCTION;

ADMINISTRATION, INHALATION; AUTOANTIBODIES; BLOOD GLUCOSE; DIABETES MELLITUS, TYPE 2; HUMANS; HYPOGLYCEMIA; INSULIN; LUNG DISEASES; PATIENT SATISFACTION; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 54049115144     PISSN: 10568727     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jdiacomp.2007.05.001     Document Type: Article

References (50)

1. American Association of Clinical Endocrinologists. State of diabetes in America. Available at:. http://www.aace.com/newsroom/press/2005/FINALDataReport.pdf (accessed December 21, 2006)
2. American Association of Clinical Endocrinologists, and American College of Endocrinology. The American Association of Clinical Endocrinologists medical guidelines for the management of diabetes mellitus: The AACE system of intensive diabetes self-management-2002 update. Endocrine Practice 8 Suppl. 1 (2002) 40-65
3. Barnett A.H. Exubera inhaled insulin: A review. International Journal of Clinical Practice 58 (2004) 394-401
4. Boss A.H., Grant M.L., and Cheatham W.W. Mimicry of the early phase insulin response in humans with rapidly available inhaled insulin accelerates postprandial glucose disposal compared to slower bioavailable insulin. Diabetes 54 (2005) A333 (Abstract 1373-P)
5. Brown J.B., Nichols G.A., and Perry A. The burden of treatment failure in type 2 diabetes. Diabetes Care 27 (2004) 1535-1540
6. Cefalu W.T., Skyler J.S., Kourides I.A., Landschulz W.H., Balagtas C.C., Cheng S., et al. Inhaled human insulin treatment in patients with type 2 diabetes mellitus. Annals of Internal Medicine 134 (2001) 203-207
7. Centers for Disease Control and Prevention, and Department of Health and Human Services. National diabetes fact sheet. Available at:. http://www.cdc.gov/diabetes/pubs/pdf/ndfs_2005.pdf (Accessed January 5, 2007)
8. Dailey G. A timely transition to insulin: Identifying type 2 diabetes patients failing oral therapy. Formulary 40 (2005) 114-130
9. DeFronzo R.A. Pharmacologic therapy for type 2 diabetes mellitus. Annals of Internal Medicine 131 (1999) 281-303
10. DeFronzo R.A., Bergenstal R.M., Cefalu W.T., Pullman J., Lerman S., Bode B.W., et al. Efficacy of inhaled insulin in patients with type 2 diabetes not controlled with diet and exercise: A 12-week, randomized, comparative trial. Diabetes Care 28 (2005) 1922-1928
11. Fineberg S.E., Kawabata T., Finco-Kent D., Liu C., and Krasner A. Antibody response to inhaled insulin in patients with type 1 or type 2 diabetes. An analysis of initial phase II and III inhaled insulin (Exubera) trials and a two-year extension trial. Journal of Clinical Endocrinology and Metabolism 90 (2005) 3287-3294
12. Freemantle N., Blonde L., Duhot D., Hompesch M., Eggertsen R., Hobbs F.D., et al. Availability of inhaled insulin promotes greater perceived acceptance of insulin therapy in patients with type 2 diabetes. Diabetes Care 28 (2005) 427-428
13. Gerich J.E. Matching treatment to pathophysiology in type 2 diabetes. Clinical Therapeutics 23 (2001) 646-659
14. Hanefeld M., Fischer S., Julius U., Schulze J., Schwanebeck U., Schmechel H., et al. Risk factors for myocardial infarction and death in newly detected NIDDM: The Diabetes Intervention Study, 11-year follow-up. Diabetologia 39 (1996) 1577-1583
15. Heise T., Bott S., Tusek C., Stephan J.A., Kawabata T., Finco-Kent D., et al. The effect of insulin antibodies on the metabolic action of inhaled and subcutaneous insulin: A prospective randomized pharmacodynamic study. Diabetes Care 28 (2005) 2161-2169
16. Hermansen K., Ronnemaa T., Petersen A.H., Bellaire S., and Adamson U. Intensive therapy with inhaled insulin via the AERx insulin Diabetes Management System: A 12-week proof-of-concept trial in patients with type 2 diabetes. Diabetes Care 27 (2004) 162-167
17. Hirsch I.B., Bergenstal R.M., Parkin C.G., Wright E., and Buse J.B. A real-world approach to insulin therapy in primary care practice. Clinical Diabetes 23 (2005) 78-86
18. Hollander P.A., Blonde L., Rowe R., Mehta A.E., Milburn J.L., Hershon K.S., et al. Efficacy and safety of inhaled insulin (Exubera) compared with subcutaneous insulin therapy in patients with type 2 diabetes: Results of a 6-month, randomized, comparative trial. Diabetes Care 27 (2004) 2356-2362
19. International Diabetes Federation. Global guideline for type 2 diabetes. Available at:. http://www.idf.org/webdata/docs/IDF%20GGT2D.pdf (Accessed October 12, 2005)
20. Jacobson A.M. Impact of improved glycemic control on quality of life in patients with diabetes. Endocrine Practice 10 (2004) 502-508
21. Jones J.G., Minty B.D., Lawler P., Hulands G., Crawley J.C.W., and Veall N. Increased alveolar epithelial permeability in cigarette smokers. Lancet 1 (1980) 66-68
22. Miller C.D., Phillips L.S., Ziemer D.C., Gallina D.L., Cook C.B., and El-Kebbi I.M. Hypoglycemia in patients with type 2 diabetes mellitus. Archives of Internal Medicine 161 (2001) 1653-1659
23. Nielsen L.L. Incretin mimetics and DPP-IV inhibitors for the treatment of type 2 diabetes. Drug Discovery Today 10 (2005) 703-710
24. Ohkubo Y., Kishikawa H., Araki E., Miyata T., Isami S., Motoyoshi S., et al. Intensive insulin therapy prevents the progression of diabetic microvascular complications in Japanese patients with non-insulin-dependent diabetes mellitus: A randomized prospective 6-year study. Diabetes Research and Clinical Practice 28 (1995) 103-117
25. Owens D.R., Zinman B., and Bolli G. Alternative routes of insulin delivery. Diabetic Medicine 20 (2003) 886-898
26. Patton J.S. Mechanisms of macromolecule absorption by the lungs. Advanced Drug Delivery Reviews 19 (1996) 3-36
27. Patton J.S. Deep-lung delivery of therapeutic proteins. Chemtech 27 (1997) 34-38
28. Peyrot M., Rubin R.R., Lauritzen T., Skovlund S.E., Snoek F.J., Matthews D.R., et al. Resistance to insulin therapy among patients and providers: Results of the cross-national Diabetes Attitudes, Wishes, and Needs (DAWN) study. Diabetes Care 28 (2005) 2673-2679
29. Pfizer. EXUBERA (insulin human [rDNA origin]) inhalation powder, EXUBERA inhaler US package insert (2006), Pfizer, New York, NY
30. Profit L. Exubera (inhaled insulin): An evidence-based review of its effectiveness in the management of diabetes. Core Evidence 1 (2005) 89-101
31. Prounis C. Improving doctor-patient relations can lead to increased patient compliance. Available at:. http://www.pharmexec.com/pharmexec/content/printContentPopup.jsp%3Fid%3D178166 (Accessed January 15, 2007)
32. Quattrin T., Belanger A., Bohannon N.J.V., Schwartz S.L., and for the Exubera Phase III Study Group. Efficacy and safety of inhaled insulin (Exubera) compared with subcutaneous insulin therapy in patients with type 1 diabetes: Results of a 6-month, randomized, comparative trial. Diabetes Care 27 (2004) 2622-2627
33. Rave K., Bott S., Heinemann L., Sha S., Becker R.H., Willavize S.A., et al. Time-action profile of inhaled insulin in comparison with subcutaneously injected insulin lispro and regular human insulin. Diabetes Care 28 (2005) 1077-1082
34. Rave K., Nosek L., De La Peña A., et al. Dose response and dose equivalency of human insulin inhalation powder (HIIP) using the Lilly/Alkermes inhaled insulin system compared to subcutaneous (SC) insulin lispro. Diabetes 54 (2005) A89 (Abstract 360-OR)
35. Rosenstock J., and Baughman R.A. A randomized, double-blind, placebo-controlled study of the efficacy and safety of inhaled Technosphere Insulin in patients with type 2 diabetes (T2DM). Diabetes 54 (2005) A88 (Abstract 357-OR)
36. Rosenstock J., Cappelleri J.C., Bolinder B., and Gerber R.A. Patient satisfaction and glycemic control after 1 year with inhaled insulin (Exubera) in patients with type 1 or type 2 diabetes. Diabetes Care 27 (2004) 1318-1323
37. Rosenstock J., Foyt H., Klioze S., Ogawa M., St Aubin L., and Duggan W. Inhaled human insulin (Exubera) therapy shows sustained efficacy and is well tolerated over a 2-year period in patients with type 2 diabetes (T2DM). Diabetes 55 Suppl. 1 (2006) A26 (Abstract 109-OR)
38. Rosenstock J., Nakano M., Silverman B., Sun B., de la Peña A., Suri A., et al. Comparison of standard (self-directed) versus intensive patient training for the human insulin inhalation powder (HIIP) delivery system in patients with type 2 diabetes: efficacy, safety, and training measures. Diabetes 55 Suppl. 1 (2006) A101 (Abstract 424-P)
39. Rosenstock J., Zinman B., Murphy L.J., Clement S.C., Moore P., Bowering C.K., et al. Inhaled insulin improves glycemic control when substituted for or added to oral combination therapy in type 2 diabetes: A randomized, controlled trial. Annals of Internal Medicine 143 (2005) 549-558
40. Sha S., Becker R.H.A., Willavise S.A., Schumacher D.A., Lee J.D., Carroll R.S., et al. The effect of smoking cessation on the absorption of inhaled insulin (Exubera). Diabetes 51 Suppl. 1 (2002) A133 (Abstract 538-P)
41. Skyler J.S., Weinstock R.S., Raskin P., Yale J.F., Barrett E., Gerich J.E., et al. Use of inhaled insulin in a basal/bolus insulin regimen in type 1 diabetic subjects: A 6-month, randomized, comparative trial. Diabetes Care 28 (2005) 1630-1635
42. Stratton I.M., Adler A.I., Neil H.A.W., Matthews D.R., Manley S.E., Cull C.A., et al. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): Prospective observational study. BMJ 321 (2000) 405-412
43. Tack C.J., Ross A.H., Baughman R.A., Hao R., Kramer D., Diaz M., et al. A randomized, double blind, placebo controlled study of the forced titration of prandial Technosphere Insulin in patients with type 2 diabetes mellitus. Diabetes 55 Suppl. 1 (2006) A102 (Abstract 428-P)
44. Triplett C.L., Reasner C.A., and Isley W.L. Diabetes mellitus. In: DiPiro J.T., Talbert R.L., Yee G.C., Matzke G.R., Wells B.G., and Posey L.M. (Eds). Pharmacotherapy: A pathophysiologic approach (2005), McGraw-Hill, New York, NY 1333-1367
45. UK Prospective Diabetes Study Group. UK prospective diabetes study 16: Overview of 6 years' therapy of type II diabetes: A progressive disease. Diabetes 44 (1995) 1249-1258
46. UK Prospective Diabetes Study Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 352 (1998) 837-853
47. Wallace T.M., and Matthews D.R. Poor glycaemic control in type 2 diabetes: A conspiracy of disease, suboptimal therapy and attitude. Q J Med 93 (2000) 369-374
48. Weiss S.R., Cheng S.-L., Kourides I.A., Gelfand R.A., Landschulz W.H., and for the Inhaled Insulin Phase II Study Group. Inhaled insulin provides improved glycemic control in patients with type 2 diabetes mellitus inadequately controlled with oral agents: A randomized controlled trial. Archives of Internal Medicine 163 (2003) 2277-2282
49. Witten M.L., Lemen R.J., Quan S.F., Sobonya R.E., Roseberry H., Stevenson J.L., et al. Acute cigarette smoke exposure increases alveolar permeability in rabbits. American Review of Respiratory Disease 132 (1985) 321-325
50. Wright A., Burden A.C.F., Paisey R.B., Cull C.A., Holman R.R., and for the UK Prospective Diabetes Study Group. Sulfonylurea inadequacy: Efficacy of addition of insulin over 6 years in patients with type 2 diabetes in the UK Prospective Diabetes Study (UKPDS 57). Diabetes Care 25 (2002) 330-336